Atelerix Awarded Innovate UK Funding to Enable Transport and Storage of Cellular Therapies at Room Temperature
Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications
Therapeutics
Scientists Identify Potential Therapeutic Targets for COVID-19
Researchers profile the body's immune response in critically ill patients
Scientists Use Microbubbles for Highly Localized Drug Release
New research shows that it is possible to manipulate microbubbles through the use of "acoustical tweezers," a tool that uses an acoustical beam to trap an object without contact
Multi-Mode Ligand Bioprocessing Technology to Facilitate Development of Advanced Therapeutics
Novel platform initially focused on high-resolution industrial scale processing of therapeutic mRNA
Solutions for Monoclonal Antibody (mAb) Therapy Discovery and Development
The use of therapeutic antibodies has shown promise as an effective cancer treatment strategy
Can a DNA Construction Kit Replace Expensive Antibody Medication?
A study in animals similar in size to humans brings us a step closer to the clinical use of antibody gene therapy
BIA Separations Introduces Cornerstone AAV Process Development Service to Accelerate Gene Therapy Production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs)
Scientists Close in on Mystery Surrounding Dangerous Blood Syndromes
Genetically driven MDS enabled by gene linked to metabolism and oxygen in cells
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE Antibodies for Cancer Targets
New project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study